SCHEMBL5086339

SCHEMBL5086339

CC(C)COC(C)(C)OCC(C)C

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30608277 0.80 MAPK1 (0.39) MAPK1ALDH1A1
SCHEMBL137282 0.80
SCHEMBL8061643 0.77 MAPK1 (0.30) MAPK1
SCHEMBL1263626 0.75
SCHEMBL1263625 0.75
SCHEMBL3888730 0.75 MAPK1 (0.36) MAPK1ALDH1A1
SCHEMBL20637050 0.75 MAPK1 (0.36) MAPK1ALDH1A1
SCHEMBL10438168 0.75
SCHEMBL8744901 0.75
SCHEMBL14777666 0.73 TSHR (0.36) MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4613785-A1 ESTER-COMPOUND-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, AND (METH)ACRYLIC POLYMER AND METHOD FOR PRODUCING SAME Mitsubishi Chemical Corporation (JP) 2025-09-10 EP disclosed
US-20250250221-A1 ESTER-COMPOUND-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, AND (METH)ACRYLIC POLYMER AND METHOD FOR PRODUCING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2025-08-07 US disclosed
WO-2024095995-A1 ESTER-COMPOUND-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, AND (METH)ACRYLIC POLYMER AND METHOD FOR PRODUCING SAME 三菱ケミカル株式会社 2024-05-10 WO disclosed
US-20130072648-A1 SOLID CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR PRODUCING OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-03-21 US disclosed
EP-1490413-A4 SOLID TITANIUM CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR OLEFIN POLYMERIZATION MITSUI CHEMICALS INC (JP) 2008-05-14 EP disclosed
EP-1490413-A1 SOLID TITANIUM CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR OLEFIN POLYMERIZATION MITSUI CHEMICALS, INC. (JP) 2004-12-29 EP disclosed
WO-2003085006-A1 SOLID TITANIUM CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR OLEFIN POLYMERIZATION MITSUI CHEMICALS, INC (JP) 2003-10-16 WO disclosed
EP-0272110-B1 ERYTHROMYCIN A DERIVATIVES AND METHOD FOR THE PREPARATION OF THE SAME TAISHO PHARMACEUTICAL CO. LTD (JP) 1993-04-07 EP disclosed
US-4990602-A Bactericides TAISHO PHARMACEUTICAL CO., LTD. (JP) 1991-02-05 US disclosed
EP-0272110-A2 Erythromycin a derivatives and method for the preparation of the same TAISHO PHARMACEUTICAL CO. LTD (JP) 1988-06-22 EP disclosed
EP-0098369-B1 PRODUCING ALKOXYSILANES AND ALKOXY-OXIMINOSILANES ALLIED CORPORATION (US) 1986-07-30 EP disclosed
EP-0098369-A2 Producing alkoxysilanes and alkoxy-oximinosilanes ALLIED CORPORATION (US) 1984-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250221-A1 ESTER-COMPOUND-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, AND (METH)ACRYLIC POLYMER AND METHOD FOR PRODUCING SAME ADCY6, ADCY5, AMD1 MAPK1 3230/4885ALDH1A1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.